“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mumbai, October 26, 2015:Pharma major Lupin Limited today announced the appointment of
Martin Mercer as its President for Latin America. He will be based at Naples, Florida. Martin joins Lupin from
Astellas Pharma where he was the Head of Latin America. Prior to that, he has worked at Valeant as Head of
Latin America & International business as well as Glaxo in Regional Management positions. He started his career
in Glaxo and worked his way through multiple roles of increasing responsibility in various Latin American
markets. Other than successfully building and scaling large businesses in diverse geographies of Latin America,
Martin has significant experience in acquisition integration, change management & restructuring, business
development and new product development.
In his new role at Lupin, Martin will assume full responsibility for the Company's Latin American business
including the company's overall strategy for its generics & specialty business in Brazil, Mexico, Venezuela,
Colombia and Argentina.
Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin Limited said, "We're delighted to
welcome Martin into the Lupin family. We believe that Martin's rich experience in Latin America will be an asset
when it comes to expanding and strengthening Lupin's businesses in the region. The Latin American region is a
market of strategic focus for the company and one of the fastest growing pharmaceutical markets globally."
About Lupin Limited
Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and
developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The
Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and
NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 6th largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions,IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 8th) and South Africa (ranked 4th – IMS Health).
For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were 125,997 million (USD 2.06 billion) and 24,032 million (USD 393 million) respectively. Please visit http://www.lupin.com for more information.
You could also follow us on Twitter – www.twitter.com/lupinlimited
CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.
For further information or queries please contact -
Head – Corporate Communications
Ph: +91 98 20 338 555
Head – M & A and Investor Relations
Ph: +91 98 20 023 511
Safe Harbor Statement